Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US
The firms are creating a CDx alliance to help pursue HRD regulatory approvals for both the MyChoice HRD assay and a future clinical IVD test from Illumina.
Myriad Genetics Q4 Revenues Rise 11 Percent on Higher Test Volumes
Myriad finished the three months ended Dec. 31 with $177.8 million in revenues compared to $160.8 million for the same quarter in 2021, beating analysts' average estimate of $169.5 million.
GenomeWeb Top 40 up 4 Percent in January, Following Broader Upswing
SomaLogic, Exact Sciences, and Myriad paced the winners in January, while Olink, a new addition to the Top 40, led decliners.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
Myriad Genetics Generates More Data on Ability of PRS to Identify Who Will Develop Breast Cancer
In a validation study presented at SABCS, Myriad evaluated how well breast cancer risk assessments made with a clinco-genomic risk score aligned with observed incidence.